Exercise targets cellular powerhouses to improve heart function — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/02/140212112749.htm
source : http://www.sciencedaily.com/releases/2014/02/140212112749.htm
source : http://www.sciencedaily.com/releases/2014/02/140207083927.htm
source : http://www.sciencedaily.com/releases/2014/01/140129075800.htm
In this paper, the authors show evidence indicating the presence of autocrine/paracrine EPO in the conditioned medium of cultured breast cancer cells and a functional role of an EPO-EPOR autocrine/paracrine loop in regulating tumor cell invasion and migration, and the stem-ness of breast cancer cells. The data support a novel paradigm wherein autocrine/paracrine EPO may regulate tumorigenesis of breast cancer via stimulating a small percentage of stem-like cancer cells or tumor-initiating cells. This mode of EPO action may explain why some studies reported in literature failed to demonstrate a pro-proliferative and pro-survival role of EPO in cancer cells when whole-populations of cancer cells were analyzed in these studies. source : http://www.sciencedaily.com/releases/2014/01/140106160121.htm
The research article by Liu et al describes MLS-2384 which is a synthetic derivative of amarine natural product, 6-bromoindirubin-3′-oxime. MLS-2384 exhibits a dual JAK/Src kinase inhibitory activity, blocks downstream signaling into the STAT3 pathway, and has anti-cancer activity in various human cancer cell lines. These findings have important clinical implications for understanding the mechanisms of action of bromoindirubin derivatives. The findings also indicate that this new 6-bromoindirubin derivative, MLS-2384, has potential as an anti-tumor therapeutic agent targeting JAK and Src kinases upstream of STAT3 in a wide variety of human cancer cells…
Glioblastoma is the most aggressive form of brain cancer, and current treatments only modestly prolong patient survival. Immune cells called T cells have the capacity to attack and kill tumor cells, but tumors can counteract this attack by creating an environment that dampens T cell activity. T cells have ways of limiting their own activation (and thus autoimmunity), one of which is to express inhibitory cell surface proteins upon activation. In other cancer models, strategies to block these inhibitory proteins have been shown to reinvigorate T cell activation and thus promote tumor regression…
A team led by Kathryn J. Ruddy, MD, MPH, and Dr. Ann H. Partridge, MD, MPH, surveyed 585 women recently diagnosed with breast cancer at or under the age of 40 years…
It is a genomic-clinical method able to determinate the prognosis of a patient with lung adenocarcinoma by studying the expression levels of 30 genes and combining the results with other indicators such as age, gender or the stage of the tumor. From this study, patients are classified into phases and from this classification depends their prognosis and treatment…
“This is exciting because we’ve found what we believe to be a ‘drugable target’ here,” says George Vasmatzis, Ph.D., a Mayo Clinic molecular medicine researcher and senior author on the study. “It’s a clear biomarker for aggressive adenocarcinomas. …